Capricor Deramiocel Faces FDA AdComm July 29 for DMD

Capricor Therapeutics (CAPR) faces a July 29 FDA advisory committee meeting for deramiocel, an allogeneic cell therapy for cardiomyopathy in Duchenne muscular dystrophy. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee will vote on the application, with a PDUFA date of August 22.

An advisory committee, or AdComm, is a panel of outside experts that reviews data and makes a non-binding recommendation to the FDA. The agency typically follows the committee’s vote but is not required to.

The rescinded CRL

The FDA previously issued a Complete Response Letter for this BLA, then rescinded it. A CRL is an FDA letter explaining why a drug application cannot be approved as submitted. The rescission signals that the agency’s concerns shifted, though the FDA has not publicly detailed what changed.

That unusual reversal frames the AdComm as a high-stakes moment. If the committee votes favorably, it would clear a path to approval on August 22. A negative vote would be a significant setback given the prior CRL history.

What deramiocel does

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells, a cell therapy with immunomodulatory and anti-fibrotic properties. Clinical studies showed preservation of cardiac and skeletal muscle function in DMD patients.

Duchenne muscular dystrophy is a severe, X-linked genetic disorder causing progressive muscle degeneration affecting skeletal, respiratory, and cardiac muscles. Cardiomyopathy is the leading cause of death in DMD patients. A cardiac-specific therapy would address the deadliest complication of the disease.

If approved, deramiocel would be the first cell therapy for DMD cardiomyopathy.

Market context

CAPR closed at $19.83 on July 23, up from $18.51 at the open, on volume of 2.01 million shares. The market cap sits near $1.1 billion. That valuation is built almost entirely on the deramiocel approval thesis.

For context on how binary catalysts move small-cap biotech stocks, see our coverage of Arrowhead’s plozasiran Phase 3 readout.

Risks

The prior CRL indicates the FDA had concerns about the data. Cell therapies face manufacturing and consistency questions, and allogeneic cell products carry additional challenges around donor variability and immune compatibility. The AdComm panel may press on durability of effect and whether the clinical data adequately supports efficacy.

DMD is also a crowded indication. Sarepta’s gene therapy Elevidys (delandistrogene moxeparvovec) is approved for ambulatory patients, and standard-of-care includes corticosteroids. Deramiocel targets the cardiac complication specifically, which differentiates it, but the competitive picture complicates the commercial outlook.

What to watch next

The July 29 committee vote. The briefing documents, typically released two business days before the meeting, will reveal the FDA’s specific concerns. Patient advocacy groups are mobilizing written testimony, which can influence the committee’s deliberation.

A positive vote does not guarantee approval, but it would significantly de-risk the August 22 PDUFA. A negative vote could send the stock sharply lower given the company’s concentrated pipeline.

FDA advisory committee meeting announcement | Capricor press release